对于阿尔茨海默氏症疾病的发病因子"撞击逃跑"假设
Tal Ganz1,2, Tamir Ben-Hur1,2
1Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
International journal of molecular sciences
|March 28, 2024
概括
可修改的风险因素可以通过触发重复的微质激活来驱动阿尔茨海默病 (AD) 神经退行,类似于感染. 这种"击中逃跑"机制影响了AD预备的大脑,表明治疗的免疫和风险因素综合管理.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种主要的神经退行性疾病.
- 新出现的证据质疑粉样斑块与神经退行症之间的直接联系.
- 粉样蛋白和沉积可能会激发大脑的免疫系统,特别是微质细胞,使其易受侮辱.
研究的目的:
- 探索可修改风险因素在阿尔茨海默氏症病原发生中的作用.
- 提出一种新的机制,其中风险因素作为外部侮辱.
- 要突出微质在风险因子中介的神经退行症中的中心作用.
主要方法:
- 对阿尔茨海默病病理学当前研究的综述.
- 分析可修改的危险因素与神经炎症之间的相互作用.
- 对风险因素诱导的神经退行症的"撞击逃跑"模型的开发.
主要成果:
- 可修改的风险因素可能会通过反复的急性微质激活诱导神经退行.
- 这个过程发生在已经受到AD病理影响的大脑区域.
- 外部侮辱可能不会留下任何直接的病理痕迹,模仿传染性"撞击逃跑".
结论:
- 微质细胞对于风险因素如何促进阿尔茨海默氏症中神经退行起到关键作用.
- 这种模型为风险因素,蛋白质病变和神经炎症之间的相互作用提供了新的视角.
- 针对免疫调节和风险因素控制可能是阿尔茨海默病的有希望的治疗策略.
相关概念视频
01:26Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184